- it stopped at phase II because the company didnt see the monetary value of it.
it's essentially the same as fin(probably a little more powerful in the right dose), yet FIN is a pill you just have to take once a day(if you take DUT you can take that even less often!) RU is a more complicated topical, so it's a tougher sell to the general population.
It was just a tough sell, RU isn't the most stable chemical and it just wasnt worth it to pursue a drug that essentially has the same effect as fin, still might cause sides(unlike CB) and may not be as stable or as easy to produce. no monetary value for the company.
CB on the other hand is being deemed as a side-effect free type of drug and potentially much more powerful, plus it has a much richer company backing it.
you also have potentially other options coming in such things as BIM which has just finished phase IIB
it's essentially the same as fin(probably a little more powerful in the right dose), yet FIN is a pill you just have to take once a day(if you take DUT you can take that even less often!) RU is a more complicated topical, so it's a tougher sell to the general population.
It was just a tough sell, RU isn't the most stable chemical and it just wasnt worth it to pursue a drug that essentially has the same effect as fin, still might cause sides(unlike CB) and may not be as stable or as easy to produce. no monetary value for the company.
CB on the other hand is being deemed as a side-effect free type of drug and potentially much more powerful, plus it has a much richer company backing it.
you also have potentially other options coming in such things as BIM which has just finished phase IIB
Comment